Ages 0 4 0 4 B-age
18 5 7 5 7 B-lower_bound
- 7 8 7 8 O
65 8 10 8 10 B-upper_bound

Concomitant 0 11 11 22 O
use 12 15 23 26 O
or 16 18 27 29 O
prior 19 24 30 35 O
use 25 28 36 39 O
in 29 31 40 42 O
the 32 35 43 46 O
preceding 36 45 47 56 B-upper_bound
6 46 47 57 58 I-upper_bound
months 48 54 59 65 I-upper_bound
of 55 57 66 68 O
any 58 61 69 72 O
investigational 62 77 73 88 O
drug 78 82 89 93 O

Diagnosis 0 9 94 103 O
of 10 12 104 106 O
scleroderma 13 24 107 118 B-chronic_disease
, 24 25 118 119 O
systemic 26 34 120 128 B-chronic_disease
fungal 35 41 129 135 I-chronic_disease
infections 42 52 136 146 I-chronic_disease
, 52 53 146 147 O
ocular 54 60 148 154 B-chronic_disease
herpes 61 67 155 161 I-chronic_disease
simplex 68 75 162 169 I-chronic_disease
, 75 76 169 170 O
congestive 77 87 171 181 B-chronic_disease
heart 88 93 182 187 I-chronic_disease
failure 94 101 188 195 I-chronic_disease
, 101 102 195 196 O
and/or 103 109 197 203 O
uncontrolled 110 122 204 216 O
hypertension 123 135 217 229 B-chronic_disease
, 135 136 229 230 O
and/or 137 143 231 237 O
any 144 147 238 241 O
clinically 148 158 242 252 O
relevant 159 167 253 261 O
medical 168 175 262 269 O
disease 176 183 270 277 O
that 184 188 278 282 O
would 189 194 283 288 O
put 195 198 289 292 O
the 199 202 293 296 O
patient 203 210 297 304 O
at 211 213 305 307 O
risk 214 218 308 312 O
by 219 221 313 315 O
participating 222 235 316 329 O
in 236 238 330 332 O
the 239 242 333 336 O
study 243 248 337 342 O

EDSS 0 4 343 347 B-clinical_variable
of 5 7 348 350 O
2.0 8 11 351 354 B-lower_bound
- 12 13 355 356 O
7.5 14 17 357 360 B-upper_bound

Failed 0 6 361 367 O
to 7 9 368 370 O
make 10 14 371 375 O
adequate 15 23 376 384 O
improvement 24 35 385 396 O
and 36 39 397 400 O
must 40 44 401 405 O
initiate 45 53 406 414 O
Acthar 54 60 415 421 B-treatment
Gel 61 64 422 425 I-treatment
therapy 65 72 426 433 I-treatment
within 73 79 434 440 O
two 80 83 441 444 B-upper_bound
weeks 84 89 445 450 I-upper_bound
( 90 91 451 452 I-upper_bound
+ 91 92 452 453 I-upper_bound
/- 92 94 453 455 I-upper_bound
72 95 97 456 458 I-upper_bound
hours 98 103 459 464 I-upper_bound
) 103 104 464 465 I-upper_bound
after 105 110 466 471 O
the 111 114 472 475 O
first 115 120 476 481 O
day 121 124 482 485 O
of 125 127 486 488 O
5 128 129 489 490 O
treatments 130 140 491 501 B-treatment
with 141 145 502 506 I-treatment
1000 146 150 507 511 I-treatment
mg 151 153 512 514 I-treatment
IVMP 154 158 515 519 I-treatment
, 158 159 519 520 O
as 160 162 521 523 O
judged 163 169 524 530 O
by 170 172 531 533 O
their 173 178 534 539 O
treating 179 187 540 548 O
neurologist 188 199 549 560 O

History 0 7 561 568 O
of 8 10 569 571 O
ACTHAR 11 17 572 578 B-treatment
gel 18 21 579 582 I-treatment
use 22 25 583 586 O
or 26 28 587 589 O
other 29 34 590 595 O
forms 35 40 596 601 O
of 41 43 602 604 O
ACTH 44 48 605 609 O
with 49 53 610 614 O
failure 54 61 615 622 O
to 62 64 623 625 O
improve 65 72 626 633 O
or 73 75 634 636 O
with 76 80 637 641 O
occurrence 81 91 642 652 O
of 92 94 653 655 O
significant 95 106 656 667 O
adverse 107 114 668 675 O
experiences 115 126 676 687 O

History 0 7 688 695 O
of 8 10 696 698 O
, 10 11 698 699 O
or 12 14 700 702 O
the 15 18 703 706 O
presence 19 27 707 715 O
of 28 30 716 718 O
, 30 31 718 719 O
a 32 33 720 721 O
peptic 34 40 722 728 B-chronic_disease
ulcer 41 46 729 734 I-chronic_disease

Pregnant 0 8 735 743 B-pregnancy

Received 0 8 744 752 O
a 9 10 753 754 O
live 11 15 755 759 B-treatment
or 16 18 760 762 I-treatment
live 19 23 763 767 I-treatment
attenuated 24 34 768 778 I-treatment
vaccine 35 42 779 786 I-treatment
in 43 45 787 789 O
the 46 49 790 793 O
last 50 54 794 798 B-upper_bound
30 55 57 799 801 I-upper_bound
days 58 62 802 806 I-upper_bound
before 63 69 807 813 O
baseline 70 78 814 822 O

Recent 0 6 823 829 O
surgery 7 14 830 837 B-treatment
( 15 16 838 839 O
up 16 18 839 841 O
to 19 21 842 844 O
the 22 25 845 848 O
investigator 26 38 849 861 O
's 38 40 861 863 O
discretion 41 51 864 874 O
what 52 56 875 879 O
constitutes 57 68 880 891 O
recent 69 75 892 898 O
) 75 76 898 899 O

Sustained 0 9 900 909 O
a 10 11 910 911 O
significant 12 23 912 923 O
MS 24 26 924 926 O
exacerbation 27 39 927 939 O
affecting 40 49 940 949 O
vision 50 56 950 956 O
, 56 57 956 957 O
brainstem 58 67 958 967 O
, 67 68 967 968 O
motor 69 74 969 974 O
, 74 75 974 975 O
or 76 78 976 978 O
cerebellar 79 89 979 989 O
function 90 98 990 998 O
AND 99 102 999 1002 O
were 103 107 1003 1007 O
initially 108 117 1008 1017 O
treated 118 125 1018 1025 O
with 126 130 1026 1030 O
a 131 132 1031 1032 O
5 133 134 1033 1034 O
day 135 138 1035 1038 O
course 139 145 1039 1045 O
of 146 148 1046 1048 O
IVMP 149 153 1049 1053 O
within 154 160 1054 1060 O
10 161 163 1061 1063 B-upper_bound
days 164 168 1064 1068 I-upper_bound
of 169 171 1069 1071 O
the 172 175 1072 1075 O
onset 176 181 1076 1081 O
of 182 184 1082 1084 O
symptoms 185 193 1085 1093 O

